Cell Therapy Market Size Worth $28.5 billion by 2026 - KBV Research

The clinical-use segment would exhibit a considerable rate during the forecast period due to the low penetration of this segment. Though, some cell therapies received approval for clinical applications like CARTISTEM, Invossa, MACI, Epicel, Cellgram-AMI, Cupistem, Cellistem IC, GINTUIT, Prochymal, and Imlygic, which would motivate the companies to put investment in this segment.

In 2019, the Allogeneic therapies segment procured the notable share of the cell therapy market. the segment would showcase a similar trend throughout the forecast period. This is owing to the various benefits with respect to the Allogeneic transplants like high availability, no requirement to recognize an HLA-matched donor, less risk of chronic complications, no risk of GVHD, and no requirement for immunosuppressive therapy. Moreover, Allogeneic therapies are less costly in comparison to allogenic therapies which can be further supporting the segment growth.

North America dominated the market in 2019. In Asia-Pacific, the cell therapy market would exhibit a promising growth rate during the forecast period. The increasing funding by the developers and consumers in educating themselves for the latest medicinal therapies would fuel the revenue generation of the emerging countries of the region. There are various stem cell consortiums in Asian Countries, which plan to ensure ordinated and organized R&D activities. In addition, patients from western countries are witnessed to move to Asian countries for treatment, due to the adaptable legal framework.

Full Report: https://www.kbvresearch.com/cell-therapy-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Fujifilm Holdings Corporation, Smith & Nephew PLC, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost Co., Ltd., Stemedica Cell Technologies, Inc., NuVasive, Inc., Avantor, Inc., Vericel Corporation, and Pharmicell Co., Ltd.

Global Cell Therapy Market Segmentation

By Therapy Type

• Autologous


• Allogeneic

By Therapeutic Area

• Malignancies


• Autoimmune Disorders


• Musculoskeletal Disorders


• Dermatology


• Others

By End User

• Academic & Research Institutes


• Hospitals & Clinics

By Cell Type

• Stem Cell


• Umbilical Cord-Derived


• Adipose-Derived Stem Cell


• Non-Stem Cell


• Bone Marrow


• Blood


• Others

By Geography

North America

• US


• Canada


• Mexico


• Rest of North America

Europe

• Germany


• UK


• France


• Russia


• Spain


• Italy


• Rest of Europe

Asia Pacific

• China


• Japan


• India


• South Korea


• Singapore


• Malaysia


• Rest of Asia Pacific

LAMEA

• Brazil


• Argentina


• UAE


• Saudi Arabia


• South Africa


• Nigeria


• Rest of LAMEA

Companies Profiled

• Fujifilm Holdings Corporation


• Smith & Nephew PLC


• Kolon TissueGene, Inc.


• JCR Pharmaceuticals Co., Ltd.


• Medipost Co., Ltd.


• Stemedica Cell Technologies, Inc.


• NuVasive, Inc.


• Avantor, Inc.


• Vericel Corporation


• Pharmicell Co., Ltd.